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Background: Recent epidemiological studies have suggested that some insulin analogues could be associated with
an increased risk of cancer. The aim of this retrospective study was to examine whether patients with diabetes
mellitus (DM) using insulin glargine have a higher tumor stage of breast carcinoma in comparison to patients using
other types of insulin.
Methods: We performed a chart review of 79 surgically treated breast carcinoma patients (mean age of 66.5 years;
range 38-86 years) who were on insulin. Insulin glargine was used in 13 patients, while the other 66 patients were
on other types of insulin. Clinical and histopathology characteristics of patients on glargine versus other types of
insulin were compared using a chi-square test and non-parametric statistical analysis.
Results: DM type 1 and DM type 2 was present in 14 and 65 patients, respectively. The mean tumor size was
2.98 cm. The TNM tumor stage at diagnosis was not higher among patients on glargine compared to patients on
other types of insulin (T1/T2 85% vs. 68%, T3/T4 15% vs. 32%, p = 0.32; N1 54% vs. 58%, p = 0.80; M1 8% vs. 6%,
respectively). No significant differences between both study groups (glargine vs. other types of insulin) were found
in the ages of the patients, their BMI, tumor histology, grade, number of metastatic lymph nodes, hormone
receptors or HER-2 status.
Conclusion: We could not show that patients with DM using insulin glargine have a higher tumor stage of breast
carcinoma in comparison to those using other types of insulin.
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Epidemiological studies show that patients with diabetes
mellitus (DM) have an increased risk of breast carcin-
oma [1]. It is known that anti-diabetic drugs may have
an impact on breast carcinoma [2,3]. Patients with type
2 diabetes exposed to sulfonylurea or exogenous insulin
had a significantly increased risk of cancer-related mor-
tality compared with patients exposed to metformin [4].
Recent epidemiological studies have suggested that some
insulin analogues could be associated with an increased
risk of cancer [5]. Observational epidemiological data
reported by Hemkens et al. [5] raised safety concerns
about the mitogenic properties of insulin glargine in* Correspondence: nbesic@onko-i.si
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reproduction in any medium, provided the orpatients with diabetes. In a recent review of the litera-
ture, Smith and Gale stated that it is currently impos-
sible to extrapolate from the in vitro to the in vivo
situation with any confidence [6].
There are conflicting data about the impact of insulin
glargine on breast cancer incidence [6-8]. Glargine,
detemir and lispro, unlike regular insulin, exhibit in vitro
proliferative and anti-apoptotic activities in a number of
cancer cell lines [9]. In vitro studies on breast cancer cell
lines showed that the serum of patients with diabetes was
a slightly stronger mitogenic when using glargine as com-
pared to detemir or insulin with intermediate duration for
action [10]. But data is scarce in the literature about clin-
ical and histopathological characteristics of tumors in
patients with breast carcinoma and DM. Our hypothesis
was that the use of glargine has an impact on the higherral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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faster progression of breast carcinoma in comparison to
other types of insulin. The aim of this retrospective study
was to examine whether patients with DM using insulin
glargine have a higher tumor stage of breast carcinoma in
comparison to patients using other insulin.
Subjects and Methods
Altogether 252 patients with DM were surgically treated
because of invasive breast carcinoma at a single institu-
tion from 2005-2011. A chart review of these 79 breast
carcinoma female patients (mean age of 66.6 years; range
38-86 years) who were on insulin was performed. Insulin
glargine was used in 13 patients, while the other 66 pa-
tients were on other types of insulin.
The data on clinical and histopathology characteristics:
the patients’ age, body mass index (BMI), TNM tumor
stage, number of metastatic lymph nodes, presence of
estrogen and progesterone receptors and HER-2 expres-
sion were collected. The tumor stage, presence of re-
gional metastases, distant metastases and residual tumor
after surgery were assessed by the TNM clinical classifi-
cation system according to UICC criteria [11] from
2007. BMI was calculated as weight/height2 (kg/m2). Co-
morbidity was evaluated by the American Society of
Anaestiologists (ASA score) [12].
In this study, routine final pathology reports were used.
Histological slides were examined by six pathologists, ex-
perienced in breast pathology. Sentinel lymph nodes were
examined by frozen section, immunohistochemistry and
paraffin section. If the sentinel nodes turned out to be
tumor-free, no further axillary surgery was recommended.
If sentinel lymph nodes showed metastases in the frozen
section, the patient underwent axillary dissection during
the same surgical procedure. In cases of malignant in-
volvement only in paraffin section or immunohistochem-
istry re-operation for axillary dissection was performed.
For the purposes of this study estrogen-receptors and
progesterone-receptors were considered positive if 10% or
more tumor cells had a positive stain. The status of HER-
2 receptors was determined by imunohistocemistry and
the FISH method. Both methods had to show a positive
result in order to classify the tumor as HER-2 positive.
Factors recorded for this study included surgical breast
cancer treatment (breast conserving operation vs. mast-
ectomy), axillary surgery (sentinel lymph node biopsy vs.
axillary dissection), adjuvant chemotherapy, hormonal
treatment and/or treatment with Trastuzumab.
The study has been reviewed by the appropriate ethics
committee and has been performed in accordance with
the ethical standards laid down in an appropriate version
of the 1964 Declaration of Helsinki. The Institutional
Review Board and Ethics Committee of the Institute of
Oncology Ljubljana have approved the study. Our studywas conducted with the understanding and consent of
the human subjects.
Statistical methods
The characteristics of patients and their treatments were
compared using contingence tables. Because of the small
number of patient groups, the ages of the patients, their
BMI, tumor size and number of metastatic lymph nodes
were compared using a Mann–Whitney rank-sum test.
For statistical analysis SPSS 16.0 for Windows was used.
In order to estimate the probability (power) to reject
the null hypothesis a “PS: Power and Sample Size Calcu-
lations” Software (Version 3.0, January 2009) was used.
An uncorrected chi-squared statistic to evaluate the null
hypothesis was used. The Type I error probability associ-
ated with this test of this null hypothesis was 0.05. In
our study there were 13 experimental subjects and 66
control subjects. The true failure rate for experimental
subjects was 0.15, while the failure rate among our con-
trols was 0.32. We are able to reject the null hypothesis
that the failure rates for experimental and control sub-
jects are equal with probability (power) 0.190. Altogether
65 experimental subjects and 305 control subjects are
needed in order to be able to reject the null hypothesis
with probability (power) 0.8.
Results
The mean age of the patients, their BMI, tumor size and
number of metastatic lymph nodes was 66.5 years,
29.9 kg/cm2, 2.98 cm and 2.65, respectively. The charac-
teristics of patients treated with glargine and other types
of insulin are presented in Table 1. Tumor-specific ther-
apy and the outcome of both groups of patients are
presented in Table 2.
The TNM stage at diagnosis was not higher among pa-
tients on glargine, compared to patients on other types
of insulin (p = 0.32). No significant differences between
the study groups were found in the ages of the patients,
their BMI, tumor histology, grade, number of metastatic
lymph nodes, hormone receptor status or HER-2 status
(Table 1).
Discussion
Epidemiological data show that the patients with DM
have a worse prognosis and a higher risk of cancer-
related mortality in comparison to patients without DM
[13,14]. In accordance with this finding is the study of
Unterburger et al. [15] who reported a correlation be-
tween the presence of diabetes and metastatic disease.
Similarly Wolf et al. [16] found that at presentation pa-
tients with breast cancer and DM had a more advanced
stage in comparison to patients without DM. They in-
vestigated the effects of DM type 2 on breast cancer at
presentation in 79 consecutive patients with DM and
Table 1 Tumor and demographic charcateristics of 79 patients with diabetes treated with glargine and other types of
insulin
Factor Subgroup Patients on glargine Patients on other types of insulin p-value
(N = 13) (N = 66)
Median age (years) 63 67 0.30
Median tumor size (mm) 22 20 0.93
Median BMI (kg/m2) 28.6 29.75 0.51
Median ASA score 2 2 0.95
Median number of metastatic lymph nodes 1 1 0.58
Mitoses (Median) 2 2 0.72
Age (years) 70 or less 10 42 0.52
71 or more 3 24
BMI (kg/m2) less than 30 2 12 0.74
(N = 76) 30 or more 10 52
American Society of Anesthesiologists score 1 0 1 0.89
2 7 34
(N = 74) 3 5 27
Contralateral breast carcinoma No 13 64 1.00
Yes 0 2
Another malignancy No 12 58 1.00
Yes 1 8
Type of diabetes mellitus DM type 1 4 10 0.23
DM type 2 9 56
Therapy with metformine No 11 54 1.00
Yes 2 12
Therapy with sulfonylurea No 12 58 1.00
Yes 1 8




T3 or T4 stage pT1 or pT2 11 45 0.32
pT3 or pT4 2 21
N stage pN0 6 28 0.80
pN1 or pN2 7 38
Number of metastatic lymph nodes 0 6 28 0.95
1–3 4 20
4 or more 3 18
M stage M0 12 62 1.00
M1 1 4
Type of invasive carcinoma Ductal 10 57 0.41
Lobular or other types 3 9
Tumor differentiation Well or moderate 6 35 0.65
Poor 7 31
Estrogen hormone status (10% or more) Positive 10 61 0.12
Negative 3 5
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Table 1 Tumor and demographic charcateristics of 79 patients with diabetes treated with glargine and other types of
insulin (Continued)
Progesteron hormone status (10% or more) Positive 8 49 0.35
Negative 5 17
HER-2 Negative 13 62 1.00
Positive 0 4
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tients who did not have DM [16]. This finding could not
be attributed to parity, family history of breast cancer,
obesity, or other risk factors for breast cancer [17]. But
Guastamacchia et al. [18], in post-menopausal patients,
found no association between DM and breast cancer
stage or hormone-receptor status comparing 77 patients
with DM and 578 controls. Furthermore, they found that
tumors of insulin-treated women had a lower prolifera-
tive activity of breast carcinoma than non-insulin treated
ones [18].
In vitro studies on breast cancer cell lines showed that
the serum of patients with diabetes was a stronger mito-
genic when using glargine as compared to other types of
insulin [10]. Our hypothesis was that the use of glargine
has an impact on the mitogenic effect on tumor cells
and so on the faster progression of breast carcinoma in
comparison to other types of insulin. Therefore, the
aim of our study was to examine whether patients with
DM using insulin glargine have a higher tumor stage of
breast carcinoma in comparison to patients using other
types of insulin. We could not show that patients with
DM using insulin glargine have a higher tumor stage of
breast carcinoma in comparison to those using other typesTable 2 Carcinoma-related treatment of patients with diabete
insulin
Factor Subgroup
Breast surgical procedure Quadrantectomy or lumpectomy Mastectom











Died of diseaseof insulin. Furthermore, no significant differences between
the study groups were found in the ages of the patients,
their BMI, tumor histology, number of metastatic lymph
nodes, hormone receptor status or HER-2 status. Also fac-
tors which correlate with the mitogenic effect did not dif-
fer in glargine users in comparison to patients on other
types of insulin. Neither the mitosis rate of tumors or
tumor grade was significantly different in both groups of
patients. Based on these results we believe that insulin
glargine does not express a mitogenic effect in vivo in
breast cancer patients.
Of course there are several limitations of our study. It
is retrospective, observational and nonrandomized. Be-
cause of the small number of patients in our study we
were able to reject the null hypothesis that the failure
rates for experimental and control subjects are equal
with probability (power) of only 0.190. Besides, because
of the small number of patients we could not take into
account the dose of insulin, in spite of the fact that we
were aware that the possibility of association between
cancer and higher glargine doses suggests that dosages
should always be considered when assessing the possible
association of insulin and its analogues with cancer [19].
Furthermore, different combinations of anti-diabetics in group of patients on glargine and other types of
Patients on glargine Patients on other types of insulin p-value
(N = 13) (N = 66)
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other types of insulin were used in our patients. More-
over, our glargine group comprised only thirteen pa-
tients. Yet, to our knowledge, it is the largest group of
patients on glargine compared to other types of insu-
lin in which the TNM stage and histological charac-
teristic of tumors were compared. All the patients
with breast carcinoma and DM on any type of insulin
were included in our study in order to avoid selection
bias.They were treated in a seven year period at a
single tertiary cancer comprehensive center, in which
about 800 surgical procedures because of breast car-
cinoma are performed annually. About two thirds of
all breast carcinoma patients from our country are
surgically treated at our center, therefore we believe
that our study adequately represents the Slovenian breast
cancer population.
Interestingly, despite both DM and breast carcinoma
being common diseases, the data about histopathology
characteristics and the extent of the disease in these pa-
tients in the literature are scarce and conflicting. In
comparison to data reported by Jiralensong et al. [3], our
patients are older and have a lower mean BMI index.
Furthermore, our patients have a lower proportion of
triple negative tumors and HER-2 positive tumors, prob-
ably because the majority of our patients are postmeno-
pausal. On the other hand, the characteristics of our
patients are comparable to patients reported by Wolf
et al. [16]. The mean age of patients, their BMI index,
rate of estrogen positive tumors, progesterone positive
tumors and HER-2 positive tumors is 66.5 years,
64.9 years, 29.9 kg/cm2 and 29.7 kg/cm2, 0.89, 0.75, 0.72,
0.44, 0.05 and 0.11 in the patients from our and their
study, respectively. Unfortunately, Wolf et al. [16] did
not analyze the impact of anti-diabetic treatment on the
cancer tumor stage of patients with DM.
The direct biological effects of DM for patients with
breast cancer are difficult to define, mainly because of
the presence of confounding factors such as obesity, old
age, co-morbidity, and differences in screening use or
treatment allocation [17]. We agree with reports from
the literature that anti-diabetic drugs may have an im-
pact on breast carcinoma [2,3]. But, based on the results
of our study, we could not confirm that insulin glargine
in comparison to other types of insulin causes faster
tumor progression. We share the opinion of Hemkens
et al. [5] that prospective long-term studies are needed
to further evaluate the safety of insulin analogues.
Conclusion
The TNM tumor stage of patients with breast carcinoma
and diabetes mellitus at diagnosis was not higher among
13 patients on glargine compared to 69 patients on other
types of insulin. Furthermore, there was no significantdifference in the mitosis rate of tumors or tumor grade
among both groups of patients.
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